LoPiccolo, Jaclyn http://orcid.org/0000-0003-0043-0206
Gusev, Alexander
Christiani, David C.
Jänne, Pasi A. http://orcid.org/0000-0002-7821-4928
Article History
Accepted: 28 November 2023
First Online: 9 January 2024
Competing interests
: P.A.J. declares consultancy roles for Abbvie, Accutar Biotech, Allorion Therapeutics, AstraZeneca, Bayer, Biocartis, Boehringer Ingelheim, Chugai Pharmaceuticals, Daiichi Sankyo, DualityBio, Eisai, Eli Lilly, Frontier Medicines, Hongyun Biotechnology, Merus, Mirati Therapeutics, Monte Rosa, Novartis, Nuvalent, Pfizer, Roche/Genentech, Sanofi, Scorpion Therapeutics, SFJ Pharmaceuticals, Silicon Therapeutics, Syndax, Takeda Oncology, Transcenta and Voronoi; stock ownership in Gatekeeper Pharmaceuticals; research funding from AstraZenenca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, PUMA Biotechnology, Revolution Medicines and Takeda Oncology<b>;</b> and post-marketing royalties from Dana-Farber Cancer Institute-owned intellectual property relating to <i>EGFR</i> mutations that has been licensed to Lab Corp. The other authors declare no competing interests.